Primary Treg transcriptome study: selection of most prominently regulated gene transcripts in GVHD compared with no GVHD and healthy donors
| Gene symbol . | Gene title . | FC GVHD 90 days vs no GVHD 90 days . | FC GVHD 90 days vs HD . | FC no GVHD 90 days vs HD . | FC GVHD 150 days vs no GVHD 150 days . | FC GVHD 150 days vs HD . | FC no GVHD 150 days vs HD . | Probe set ID . | Unigene . |
|---|---|---|---|---|---|---|---|---|---|
| CDKN2B | Cyclin-dependent kinase inhibitor 2B | 2.8 | 4.5 | 2.0 | 3.2 | 6.5 | 2.5 | 236313_at | Hs.729 01 |
| CDK6 | Cyclin-dependent kinase 6 | 2.4 | 2.4 | 2.0 | 2.8 | 2.0 | NR | 224851_at | Hs.119882 |
| LAG3 | Lymphocyte-activation gene 3 | −2.3 | NR | NR | −2.1 | NR | NR | 206486_at | Hs.409523 |
| CD44 | CD44 molecule (Indian blood group) | −2.9 | NR | 2.0 | −4.4 | −1.6 | 2.6 | 209835_x_at | Hs.502328 |
| GZMA | Granzyme A | −3.4 | NR | 1.6 | −2.9 | NR | NR | 205488_at | Hs.907 08 |
| CXCR6 | Chemokine (C-X-C motif) receptor 6 | −3.8 | −3.3 | NR | −2.0 | NR | NR | 206974_at | Hs.345 26 |
| LGALS1 | Galectin-1 | −1.9 | NR | 1.7 | −2.8 | −1.8 | NR | 201105_at | Hs.445351 |
| CCR5 | Chemokine (C-C motif) receptor 5 | −4.4 | 1.5 | 1.5 | −1.9 | NR | −1.8 | 206991_s_at | Hs.536735 |
| CCR3 | Chemokine (C-C motif) receptor 3 | −5.7 | NR | 1.5 | −1.6 | 1.9 | −1.6 | 208304_at | Hs.506190 |
| CCR1 | Chemokine (C-C motif) receptor 1 | −6.4 | 3.8 | 11.0 | −1.5 | 1.9 | 1.6 | 205098_at | Hs.301921 |
| CXCR3 | Chemokine (C-X-C motif) receptor 3 | −6.3 | NR | 3.0 | −2.3 | 2.2 | 3.4 | 207681_at | Hs.198252 |
| Gene symbol . | Gene title . | FC GVHD 90 days vs no GVHD 90 days . | FC GVHD 90 days vs HD . | FC no GVHD 90 days vs HD . | FC GVHD 150 days vs no GVHD 150 days . | FC GVHD 150 days vs HD . | FC no GVHD 150 days vs HD . | Probe set ID . | Unigene . |
|---|---|---|---|---|---|---|---|---|---|
| CDKN2B | Cyclin-dependent kinase inhibitor 2B | 2.8 | 4.5 | 2.0 | 3.2 | 6.5 | 2.5 | 236313_at | Hs.729 01 |
| CDK6 | Cyclin-dependent kinase 6 | 2.4 | 2.4 | 2.0 | 2.8 | 2.0 | NR | 224851_at | Hs.119882 |
| LAG3 | Lymphocyte-activation gene 3 | −2.3 | NR | NR | −2.1 | NR | NR | 206486_at | Hs.409523 |
| CD44 | CD44 molecule (Indian blood group) | −2.9 | NR | 2.0 | −4.4 | −1.6 | 2.6 | 209835_x_at | Hs.502328 |
| GZMA | Granzyme A | −3.4 | NR | 1.6 | −2.9 | NR | NR | 205488_at | Hs.907 08 |
| CXCR6 | Chemokine (C-X-C motif) receptor 6 | −3.8 | −3.3 | NR | −2.0 | NR | NR | 206974_at | Hs.345 26 |
| LGALS1 | Galectin-1 | −1.9 | NR | 1.7 | −2.8 | −1.8 | NR | 201105_at | Hs.445351 |
| CCR5 | Chemokine (C-C motif) receptor 5 | −4.4 | 1.5 | 1.5 | −1.9 | NR | −1.8 | 206991_s_at | Hs.536735 |
| CCR3 | Chemokine (C-C motif) receptor 3 | −5.7 | NR | 1.5 | −1.6 | 1.9 | −1.6 | 208304_at | Hs.506190 |
| CCR1 | Chemokine (C-C motif) receptor 1 | −6.4 | 3.8 | 11.0 | −1.5 | 1.9 | 1.6 | 205098_at | Hs.301921 |
| CXCR3 | Chemokine (C-X-C motif) receptor 3 | −6.3 | NR | 3.0 | −2.3 | 2.2 | 3.4 | 207681_at | Hs.198252 |
Differential gene expression changes are presented as fold change (FC) comparing GVHD with immune tolerant (no GVHD) patients early (90 days) and late (150 days) after SCT and sex- and age-matched healthy donors (HD), respectively.
NR indicates not regulated.